Literature DB >> 34465608

Proteins Associated with Risk of Kidney Function Decline in the General Population.

Morgan E Grams1,2, Aditya Surapaneni2, Jingsha Chen2, Linda Zhou2, Zhi Yu2, Diptavo Dutta3, Paul A Welling4, Nilanjan Chatterjee3, Jingning Zhang3, Dan E Arking5, Teresa K Chen4, Casey M Rebholz2, Bing Yu6, Pascal Schlosser2,7, Eugene P Rhee8, Christie M Ballantyne9, Eric Boerwinkle6,10, Pamela L Lutsey11, Thomas Mosley12, Harold I Feldman13, Ruth F Dubin14, Peter Ganz14, Hongzhe Lee13, Zihe Zheng13, Josef Coresh4,2,3.   

Abstract

BACKGROUND: Proteomic profiling may allow identification of plasma proteins that associate with subsequent changesin kidney function, elucidating biologic processes underlying the development and progression of CKD.
METHODS: We quantified the association between 4877 plasma proteins and a composite outcome of ESKD or decline in eGFR by ≥50% among 9406 participants in the Atherosclerosis Risk in Communities (ARIC) Study (visit 3; mean age, 60 years) who were followed for a median of 14.4 years. We performed separate analyses for these proteins in a subset of 4378 participants (visit 5), who were followed at a later time point, for a median of 4.4 years. For validation, we evaluated proteins with significant associations (false discovery rate <5%) in both time periods in 3249 participants in the Chronic Renal Insufficiency Cohort (CRIC) and 703 participants in the African American Study of Kidney Disease and Hypertension (AASK). We also compared the genetic determinants of protein levels with those from a meta-analysis genome-wide association study of eGFR.
RESULTS: In models adjusted for multiple covariates, including baseline eGFR and albuminuria, we identified 13 distinct proteins that were significantly associated with the composite end point in both time periods, including TNF receptor superfamily members 1A and 1B, trefoil factor 3, and β-trace protein. Of these proteins, 12 were also significantly associated in CRIC, and nine were significantly associated in AASK. Higher levels of each protein associated with higher risk of 50% eGFR decline or ESKD. We found genetic evidence for a causal role for one protein, lectin mannose-binding 2 protein (LMAN2).
CONCLUSIONS: Large-scale proteomic analysis identified both known and novel proteomic risk factors for eGFR decline.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  ESKD; proteomics

Mesh:

Year:  2021        PMID: 34465608      PMCID: PMC8729856          DOI: 10.1681/ASN.2020111607

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  49 in total

1.  Meta-analysis identifies six new susceptibility loci for atrial fibrillation.

Authors:  Patrick T Ellinor; Kathryn L Lunetta; Christine M Albert; Nicole L Glazer; Marylyn D Ritchie; Albert V Smith; Dan E Arking; Martina Müller-Nurasyid; Bouwe P Krijthe; Steven A Lubitz; Joshua C Bis; Mina K Chung; Marcus Dörr; Kouichi Ozaki; Jason D Roberts; J Gustav Smith; Arne Pfeufer; Moritz F Sinner; Kurt Lohman; Jingzhong Ding; Nicholas L Smith; Jonathan D Smith; Michiel Rienstra; Kenneth M Rice; David R Van Wagoner; Jared W Magnani; Reza Wakili; Sebastian Clauss; Jerome I Rotter; Gerhard Steinbeck; Lenore J Launer; Robert W Davies; Matthew Borkovich; Tamara B Harris; Honghuang Lin; Uwe Völker; Henry Völzke; David J Milan; Albert Hofman; Eric Boerwinkle; Lin Y Chen; Elsayed Z Soliman; Benjamin F Voight; Guo Li; Aravinda Chakravarti; Michiaki Kubo; Usha B Tedrow; Lynda M Rose; Paul M Ridker; David Conen; Tatsuhiko Tsunoda; Tetsushi Furukawa; Nona Sotoodehnia; Siyan Xu; Naoyuki Kamatani; Daniel Levy; Yusuke Nakamura; Babar Parvez; Saagar Mahida; Karen L Furie; Jonathan Rosand; Raafia Muhammad; Bruce M Psaty; Thomas Meitinger; Siegfried Perz; H-Erich Wichmann; Jacqueline C M Witteman; W H Linda Kao; Sekar Kathiresan; Dan M Roden; Andre G Uitterlinden; Fernando Rivadeneira; Barbara McKnight; Marketa Sjögren; Anne B Newman; Yongmei Liu; Michael H Gollob; Olle Melander; Toshihiro Tanaka; Bruno H Ch Stricker; Stephan B Felix; Alvaro Alonso; Dawood Darbar; John Barnard; Daniel I Chasman; Susan R Heckbert; Emelia J Benjamin; Vilmundur Gudnason; Stefan Kääb
Journal:  Nat Genet       Date:  2012-04-29       Impact factor: 38.330

2.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

3.  Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis.

Authors:  Valerie S LeBleu; Yingqi Teng; Joyce T O'Connell; David Charytan; Gerhard A Müller; Claudia A Müller; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-01-27       Impact factor: 53.440

4.  An atlas of genetic associations in UK Biobank.

Authors:  Oriol Canela-Xandri; Konrad Rawlik; Albert Tenesa
Journal:  Nat Genet       Date:  2018-10-22       Impact factor: 38.330

5.  The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.

Authors:  Francis Verbeke; Justyna Siwy; Wim Van Biesen; Harald Mischak; Anneleen Pletinck; Eva Schepers; Nathalie Neirynck; Pedro Magalhães; Martin Pejchinovski; Claudia Pontillo; Ralf Lichtinghagen; Korbinian Brand; Antonia Vlahou; Dirk De Bacquer; Griet Glorieux
Journal:  Nephrol Dial Transplant       Date:  2021-04-26       Impact factor: 5.992

6.  HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure.

Authors:  Arnold Piek; Wouter C Meijers; Nicolas F Schroten; Ron T Gansevoort; Rudolf A de Boer; Herman H W Silljé
Journal:  J Card Fail       Date:  2016-05-17       Impact factor: 5.712

7.  Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects.

Authors:  Guanghao Qi; Nilanjan Chatterjee
Journal:  Nat Commun       Date:  2019-04-26       Impact factor: 14.919

8.  The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

Authors:  Nicole E James; Jenna B Emerson; Ashley D Borgstadt; Lindsey Beffa; Matthew T Oliver; Virginia Hovanesian; Anze Urh; Rakesh K Singh; Rachael Rowswell-Turner; Paul A DiSilvestro; Joyce Ou; Richard G Moore; Jennifer R Ribeiro
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

9.  PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations.

Authors:  Mihir A Kamat; James A Blackshaw; Robin Young; Praveen Surendran; Stephen Burgess; John Danesh; Adam S Butterworth; James R Staley
Journal:  Bioinformatics       Date:  2019-11-01       Impact factor: 6.937

10.  A flexible and accurate genotype imputation method for the next generation of genome-wide association studies.

Authors:  Bryan N Howie; Peter Donnelly; Jonathan Marchini
Journal:  PLoS Genet       Date:  2009-06-19       Impact factor: 5.917

View more
  2 in total

1.  Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Ali Javaheri; Ahmed Diab; Lei Zhao; Chenao Qian; Jordana B Cohen; Payman Zamani; Anupam Kumar; Zhaoqing Wang; Christina Ebert; Joseph Maranville; Erika Kvikstad; Michael Basso; Vanessa van Empel; A Mark Richards; Robert N Doughty; Ernst Rietzschel; Karl Kammerhoff; Joseph Gogain; Peter Schafer; Dietmar A Seiffert; David A Gordon; Francisco Ramirez-Valle; Douglas L Mann; Thomas P Cappola; Julio A Chirinos
Journal:  Circ Heart Fail       Date:  2022-08-09       Impact factor: 10.447

2.  APOL1 Kidney Risk Variants and Proteomics.

Authors:  Teresa K Chen; Aditya L Surapaneni; Dan E Arking; Christie M Ballantyne; Eric Boerwinkle; Jingsha Chen; Josef Coresh; Anna Köttgen; Katalin Susztak; Adrienne Tin; Bing Yu; Morgan E Grams
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-26       Impact factor: 10.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.